A basic rundown matching Ozempic and Wegovy to semaglutide and Mounjaro and Zepbound to tirzepatide, both used for weight management.
Recap by typeshit. Post by Facebook on Facebook.
Chokshi notes the sales were 0.4% of Lilly's $23 billion quarter, and that Divi's Labs hasn't announced any role in making the drug.
The surgeon says that after a 45 lb loss on a GLP-1, getting enough daily protein with a low appetite becomes the harder part.
She says the cause is a calorie surplus: some patients still manage high calorie foods and aren't exercising enough while on the drugs.
A short piece on how cravings and snacking urges may change for people taking GLP-1 drugs. Details are thin, so tap through for the full story.
PBS News reports that cost remains a major barrier for many patients, even after some recent improvements in GLP-1 access.
An indirect comparison shown at EASD 2026 put orforglipron ahead of Rybelsus at 52 weeks. GlobalData's analyst says head-to-head trials are still needed.
Loading…